Established in 1986, EB Pharma is an integrated pharmaceutical company focused on sales and marketing. We maximize the value of innovator drug brands, which can begin from any stage of the product-life-cycle, by driving sales, increasing market share, and delivering share of voice, before finally purchasing carryover products should innovators choose to divest, or assisting in a planned withdrawl. In addtion to innovator products, we also carry a portfolio of generic products through contract research and toll manufacturing.
We collaborate with suppliers, distributors, and healthcare providers to provide products and services of the best quality to all patients. We emphasize integrity, performance, and teamwork, expecting our colleagues to aggressively engage in personal work, collaborating with team members and complying with changing corporate strategies, at the same time never compromising on business ethics.
To ensure the complaince of our business practices, all employees are required to sign and agree to the Code of Conduct and receive annual retraining. The Code of Conduct can be downloaded from the link below:
Download
Established
Started to market Zatiden for Northern Taiwan for Sandoz
Started to market Voltaren for Northern Taiwan for Ciba-Geigy
With Sandoz and Ciba-Geigy merged to become Novartis, EB Pharma became the largest distributor of Novartis in Taiwan, marketing more products such as Parlodel, Clozaril, Etumine, and Hydergine
Started to develop own branded generic products in Taiwan
Meto 250mg (Metformin) launched
Suride 200mg (Sulpiride) launched
Epram 10mg (Escitalopram) and Pane 40mg IV (Pantoprazole) launched
Fute 0.5/5mg (Flupentixol) launched
Epine 25/200/300mg (Quetiapine) launched
Cibacen and Nitroderm TTS were added to our Novartis portfolio
Trileptal and Tegretol were added to our Novartis portfolio
Financial reports began to be audited by KPMG
Ritalin IR and Ritalin LA were added to our Novartis portfolio
Acquired Tofranil franchise in Taiwan
Exelon was added to our Novartis portfolio; Ezole 2/5mg (Aripiprazole) launched; Exprexa 5/10mg (Olanzapine) launched; Exprexa 10mg Lyophilized Injection (Olanzapine) launched
Gilenya and Mayzent were added to our Novartis portfolio
Acquired Dalmadorm franchise in Taiwan; Revenue exceeded NT$ 1 billion